The present data contribute to a better understanding of the pathological relevance of MAP4K1 and the underlying mechanisms in GBM progression, indicating that MAP4K1 is a potential molecular therapeutic target for malignant gliomas. The gene discussed is MAP4K1; the disease is malignant glioma.